Print

Purpose

This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of primary AL amyloidosis of tissue - Relapsed and/or refractory AL amyloidosis - Has received daratumumab or Faspro in any prior line of therapy - Prior pomalidomide exposure allowed if ≥ PR achieved and no disease progression occurred within 60 days of last dose received - Measurable disease - Able to give voluntary written consent - Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2. - Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3. - Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN) (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. - eGFR ≥ 20 mL/min/1.73 m2 (as calculated by Modified Diet in Renal Disease (MDRD) formula)

Exclusion Criteria

  • Non-AL amyloidosis - Clinically overt myeloma - Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies. - Clinically significant cardiac disease - Severe obstructive airway disease - Female patients who are lactating or have a positive serum pregnancy test during the screening period - Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment. - Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy. - Major surgery within 14 days before enrollment. - Radiotherapy within 14 days before enrollment. - Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort. - Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C - Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
daratumumab/pomalidomide/dexamethasone 		Pomalidomide: (4mg orally) on days 1-21 of a 28-day cycle Dexamethasone: - 20mg IV as premedication on days 1, 8, 15, and 22 - 20mg orally the day after daratumumab dosing for cycles 1-2 of induction - 40mg IV as premedication on days 1 and 15 on daratumumab treatment days - 40mg orally on non-daratumumab days (8 and 15) for cycles 3-6 - 20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond) - If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction. Daratumumab: - 1800mg sub-cutaneously weekly x8 weeks - 1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6) - 1800mg sub-cutaneously every 4 weeks cycles 7 and beyond
  • Drug: Daratumumab SC
    Given as 1800mg via injection
    Other names:
    • Faspro
  • Drug: Pomalidomide
    Given as 4mg oral capsule
  • Drug: Dexamethasone
    Given as 20mg or 40 mg IV and 20mg or 40mg oral tablet.

Recruiting Locations

Boston University Medical Center
Boston, Massachusetts 02118
Contact:
Vaishali Sanchorawala, MD
Vaishali.Sanchorawala@bmc.org

More Details

Status
Recruiting
Sponsor
Weill Medical College of Cornell University

Study Contact

Kathleen P Research Nurse Coordinator, RN
646-962-6500
kap9111@med.cornell.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.